Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

On location

Olutasidenib Shows Promise for Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia

Olutasidenib, an investigational IDH1 inhibitor selective for mutant IDH1, was well tolerated and associated with durable complete remissions (CRs) in patients with high-risk, relapsed/refractory...
On location

How Do Perceptions about Side Effects Influence Treatment Decisions and Outcomes in AML?

Patients’ negative perception of the side effects of intensive chemotherapy (IC) for acute myeloid leukemia (AML) may be associated with undertreatment and worse outcomes,...

Comparing Real-World Versus Clinical Trial Outcomes for Acute Promyelocytic Leukemia

A recent study published in Leukemia & Lymphoma examined one-month mortality and overall survival (OS) data of patients diagnosed with acute promyelocytic leukemia (APL)...

Can Caloric Restriction Improve Chemotherapy Response in Overweight Patients With ALL?

Previous reports have found that patients who are overweight or obese during B-cell acute lymphocytic leukemia (B-ALL) induction therapy are at a higher risk...

Next-Generation Karyotyping Outperforms Conventional Cytogenetics for Prognostication of AML

Compared with conventional cytogenetic analysis (CCA), next generation sequencing (NGS)–based karyotyping offered greater insight into the prognosis of patients with intensively treated acute myeloid...

Universal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML

Initial findings from a proof-of-concept study led by Martin Wermke, MD, from the Technical University of Dresden in Germany, suggest that UniCAR, a universal,...

Cellular Therapies Hold Promise in Myeloid Malignancies

There is hope that these therapies will improve outcomes, but development is still in early stages.  A recent spate of approvals of targeted treatments, such...

Daunorubicin and Cytarabine Combination Approved for Pediatric Secondary AML

The U.S. Food and Drug Administration (FDA) has approved a revised label for liposomal daunorubicin and cytarabine, CPX 351, to include a new indication...

Is Pretransplant Disease Reduction Necessary in MDS and AML?

For patients with myelodysplastic syndromes (MDS) or low-blast secondary acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (AHCT) is the only potentially curative treatment...

Kronos Bio Announces Phase III Trial of Entospletinib in NPM1-Mutated AML

Kronos Bio says it has reached an agreement with the U.S. Food and Drug Administration (FDA) to launch a phase III clinical trial evaluating...
Advertisement

Current Issue

December 2021 Volume 7 Issue 15

This issue explores doctor deserts, celebrates the 50th anniversary of the National Cancer Act, and more.

Block title